Drugging PI3K in cancer: refining targets and therapeutic strategies

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The phosphatidylinositol-3 kinase (PI3K) pathway is a key signaling route frequently dysregulated in human cancers.
• Targeting the PI3K pathway is a critical strategy for developing novel anticancer drugs and advancing precision medicine.

Purpose of the Study:

• To review the progress in the discovery and development of novel PI3K inhibitors.
• To emphasize the antitumour activity and tolerability of PI3K inhibitors in clinical trials.
• To discuss challenges such as drug resistance and patient selection, and explore rational combination therapies.

Main Methods:

• Review of clinical trial data for PI3K inhibitors.
• Analysis of antitumour activity and safety profiles.
• Discussion of resistance mechanisms and combination strategies.

Main Results:

• Over 30 small molecule PI3K inhibitors have advanced into clinical trials.
• The PI3Kδ inhibitor idelalisib received regulatory approval for B-cell malignancies.
• Various PI3K inhibitor classes, including dual PI3K/mTOR, pan-Class I PI3K, and isoform-selective inhibitors, are under investigation.

Conclusions:

• Significant progress has been made in developing PI3K inhibitors for cancer treatment.
• Addressing drug resistance and optimizing patient selection are key for future success.
• Targeted combinations hold promise for enhancing therapeutic outcomes in various malignancies.